AxoGen (AXGN) AI Stock Analysis

• Market Cap: $1.65B
• Dividend Yield: N/A
• Average Volume (3M): 801.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: 18.72%
• EPS Growth: 85.77%
• Country: US
• Employees: 451
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.07
• Shares Outstanding: 51,897,682
• 10 Day Avg. Volume: 462,742
• 30 Day Avg. Volume: 801,935
• PEG Ratio: -2.01
• Price to Book (P/B): 11.70
• Price to Sales (P/S): 6.69
• P/FCF Ratio: -513.89
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 7.00
• Enterprise Value/Gross Profit: 9.41
• Enterprise Value/Ebitda: 178.55
• 1Y Price Target: $40.25
• Price Target Upside: 26.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): 0.5
• Revenue Forecast (FY): $265.15M

• Rating: 56 Neutral
• Price Target: $33.00 ▲(4.00% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is driven primarily by improving fundamentals (strong revenue growth, high gross margins, and sharply reduced debt) but is held back by ongoing GAAP losses and negative TTM free cash flow. The latest earnings call was constructive with ≥18% growth guidance and an expectation of full-year 2026 free-cash-flow positivity, while technicals are mixed with a softer near-term trend.

Positive Factors

Sustained revenue growth and commercial adoption

Multi-year top-line momentum and broad market uptake signal durable commercial traction. Double-digit growth across extremities, OMH&N and breast plus rising active surgeons and high-potential account productivity underpin repeatable procedure-driven revenue expansion over the next 2–6 months.

High gross margins and improving adjusted EBITDA

Sustained ~74–76% gross margins and materially improved adjusted EBITDA reflect strong unit economics and operating leverage in implantable biologics and surgical adjuncts. This margin profile supports reinvestment and should enable durable profitability as scale and mix stabilize post-BLA transition.

FDA BLA approval with long exclusivity and strategic positioning

Regulatory conversion to an FDA-approved biologic with 12 years exclusivity is a structural competitive advantage. It strengthens clinical and payer credibility, supports differentiated positioning versus non‑biologic alternatives, and creates a foundation for prioritized studies and durable reimbursement gains.

Negative Factors

Ongoing GAAP losses and negative free cash flow

Despite improved adjusted EBITDA and operating cash flow, persistent TTM GAAP losses and negative FCF indicate the firm has not yet converted improved operating results into consistent owner‑level profitability and cash generation, leaving sensitivity to execution or reimbursement setbacks.

Incomplete payer coverage and reimbursement risk

Material pockets of uncovered lives and uneven payer adoption create structural revenue uncertainty. Durable procedure uptake depends on broader commercial coverage; delays or slower-than-expected reimbursement wins can constrain adoption, pricing power and predictable mid-term revenue growth.

High operating expense intensity and heavy S&M investment

Aggressive sales force expansion and higher R&D/G&A increase fixed cost leverage and pressure margins until productivity gains materialize. If surgeon activation or high‑potential account targets underperform, ongoing high Opex could prolong losses or require additional capital to sustain growth.

AxoGen Business Overview & Revenue Model

Company Description

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

How the Company Makes Money

AxoGen generates revenue primarily through the sale of its products, including Avance Nerve Graft and AxoGuard Nerve Connector, to hospitals and surgical centers across the United States. The company employs a direct sales force that engages with surgeons and healthcare providers to promote its products and educate them on the benefits and applications of nerve repair solutions. Key revenue streams also include reimbursement from insurance companies for the use of their products in surgical procedures. Additionally, AxoGen may enter into strategic partnerships with other medical device companies or research institutions to enhance product development and expand its market reach, contributing to its overall earnings.

AxoGen Financial Statement Overview

Summary

Revenue is rising and gross margins are strong (~75%), with operating results improving toward break-even and debt reduced materially. However, the company is still loss-making (TTM net loss ~$15.7M) and free cash flow remains negative in TTM (~-$3.3M), keeping the financial profile mixed.

Income Statement

Top-line momentum is solid, with revenue rising to $225.2M in TTM (Trailing-Twelve-Months) (+4.9%) and a multi-year upward trend. Profitability is improving versus prior years: operating results have moved from deeply negative to near break-even and EBITDA is positive in TTM, supported by strong ~75% gross margins. The key weakness remains bottom-line losses (TTM net loss of ~$15.7M), indicating the business has not yet reached consistent profitability.

Balance Sheet

Leverage looks manageable and has improved materially: total debt declined to ~$19.2M in TTM (Trailing-Twelve-Months) from ~$68.7M in 2024, and debt is moderate relative to equity. Equity has grown to ~$128.8M and assets to ~$221.7M, providing a reasonable capital base. The main concern is continued losses translating into negative returns on equity, which can pressure book value over time if profitability does not improve.

Cash Flow

Cash generation is still inconsistent. Operating cash flow turned slightly positive in TTM (Trailing-Twelve-Months) (~$0.8M), a meaningful improvement from negative levels in 2021–2023, but free cash flow remains negative (~-$3.3M), reflecting ongoing investment and/or working-capital drag. While 2024 was roughly breakeven on free cash flow, the step back in TTM highlights execution risk until the company can sustain positive operating cash flow and consistently fund growth without additional financing.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	225.21M	187.34M	159.01M	138.58M	127.36M
Gross Profit	167.35M	141.98M	121.87M	108.81M	104.43M
EBITDA	192.00K	6.08M	-13.33M	-23.47M	-20.89M
Net Income	-15.70M	-9.96M	-21.72M	-28.95M	-26.98M
Balance Sheet
Total Assets	221.69M	203.73M	196.83M	195.39M	208.02M
Cash, Cash Equivalents and Short-Term Investments	35.55M	33.48M	31.02M	48.79M	84.09M
Total Debt	19.24M	68.69M	69.29M	67.43M	67.45M
Total Liabilities	92.84M	99.82M	101.16M	94.39M	95.47M
Stockholders Equity	128.85M	103.91M	95.67M	101.00M	112.55M
Cash Flow
Free Cash Flow	-2.93M	11.00K	-20.63M	-37.32M	-41.80M
Operating Cash Flow	812.00K	4.54M	-5.72M	-16.07M	-13.40M
Investing Cash Flow	-5.32M	-10.30M	19.25M	-3.20M	-23.65M
Financing Cash Flow	10.50M	2.29M	1.95M	1.79M	20.45M

AxoGen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 31.73
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AXGN, the sentiment is Negative. The current price of 31.73 is below the 20-day moving average (MA) of 33.96, below the 50-day MA of 33.00, and above the 200-day MA of 20.76, indicating a neutral trend. The MACD of -0.11 indicates Positive momentum. The RSI at 42.26 is Neutral, neither overbought nor oversold. The STOCH value of 37.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AXGN.

AxoGen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVS	64 Neutral	$726.66M	78.18	4.97%	―	1.58%	―
AVNS	59 Neutral	$655.70M	-8.95	-46.68%	―	2.70%	-3090.51%
AXGN	56 Neutral	$1.65B	-93.68	-1.90%	―	18.72%	85.77%
SIBN	56 Neutral	$685.45M	-35.12	-12.91%	―	23.27%	43.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OFIX	50 Neutral	$543.15M	-5.78	-24.60%	―	4.31%	3.26%
TNDM	45 Neutral	$1.73B	-8.24	-97.88%	―	17.87%	-57.03%

AxoGen Corporate Events

AxoGen Posts Strong Growth and Raises Capital With Offering

Axogen on February 24, 2026 reported that fourth-quarter 2025 revenue rose 21.3% year over year to $59.9 million and full-year revenue grew 20.2% to $225.2 million, driven by double-digit gains across extremities, oral maxillofacial and head and neck, and breast markets. Despite a GAAP net loss of $13.2 million in the quarter and $15.7 million for the year, the company maintained flat adjusted net income of $3.5 million for the quarter, expanded full-year adjusted net income to $14.4 million and adjusted EBITDA to $27.9 million, and increased year-end cash and investments to $45.5 million.

Profitability metrics were temporarily pressured by approximately $1.9 million of largely non-cash, one-time costs tied to the U.S. FDA’s December 3, 2025 approval of the Biologics License Application for Avance, now the only implantable biologic indicated for peripheral nerve discontinuities. Axogen further strengthened its balance sheet with a January 23, 2026 upsized equity offering that generated $133.3 million in net proceeds, enabling full repayment of its Oberland loan facility and leaving additional capital for general corporate use, while expanded payer coverage and new CMS procedure coding enhanced reimbursement and reinforced its competitive position in peripheral nerve repair.

The most recent analyst rating on (AXGN) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.

AxoGen Announces Equity Offering to Repay Term Loan

On January 21, 2026, Axogen entered into an underwriting agreement with Wells Fargo Securities and Mizuho Securities to sell 4,000,000 shares of its common stock at $31.00 per share, with a 30‑day option for underwriters to purchase an additional 600,000 shares, in an offering expected to close on January 23, 2026. The company also signed a payoff letter on January 20, 2026 with its lender Oberland Capital, setting a final payoff amount of about $69.7 million if paid by February 15, 2026, and expects to use a significant portion of the offering’s net proceeds to fully repay and terminate its term loan credit facility, which would release all related liens and strengthen its balance sheet by reducing debt obligations.

The most recent analyst rating on (AXGN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.

Axogen Announces Strong Preliminary Fourth-Quarter 2025 Revenue Growth

On January 12, 2026, Axogen reported preliminary unaudited results indicating that fourth-quarter 2025 revenue is expected to be about $59.9 million, up 21.3% year over year, while full-year 2025 revenue is projected at approximately $225.2 million, a 20.2% increase from 2024, supported by broad product portfolio demand, targeted commercial execution in extremities and head and neck markets, and growing adoption of its Resensation procedure. The company expects fourth-quarter and full-year 2025 gross margins above 74%, despite roughly $1.9 million in one-time costs tied to the U.S. FDA’s December 3, 2025 approval of Avance as a biologic therapeutic, most of which are non-cash stock-compensation charges, and it ended 2025 with an estimated $45.5 million in cash and investments—about $6 million more than a year earlier—signaling improved financial strength and reinforcing its strategic positioning in the peripheral nerve repair market; Axogen also posted an updated corporate presentation for use with investors on the same date.

The most recent analyst rating on (AXGN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.

AxoGen Approves New CFO Compensation and Agreement

On December 3, 2025, AxoGen, Inc.’s Board of Directors approved changes to the compensation package for Chief Financial Officer Lindsey Hartley. Effective January 1, 2026, her annual base salary will increase by 7%, and her target bonus opportunity will rise from 50% to 60% of her salary. Additionally, an Amended and Restated Confidentiality, Intellectual Property, Non-Competition, and Non-Solicitation Agreement was signed, effective December 5, 2025, which includes a two-year post-employment non-competition covenant.

The most recent analyst rating on (AXGN) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.

AxoGen Secures FDA Approval for Avance Nerve Scaffold

On December 3, 2025, Axogen announced that the FDA approved its Biologics License Application for Avance®, an acellular nerve scaffold for treating peripheral nerve discontinuities. This approval, under the FDA’s Accelerated Approval pathway, marks a significant regulatory milestone for Axogen, transitioning Avance from a human tissue product to a biologic classification. This shift strengthens Axogen’s regulatory position and confirms Avance as a safe and effective therapeutic option, with commercial availability expected in early 2026. The approval is contingent upon confirmatory clinical studies, and Avance remains available under the current tissue framework until then.

The most recent analyst rating on (AXGN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.